nmCRPC VL

ARAMIS Trial: PSA Responses with Darolutamide Linked to Minimal Radiographic Progression - Alicia Morgans

Details
Zach Klaassen and Alicia Morgans discuss the findings from an exploratory analysis of the ARAMIS trial, focusing on the efficacy of darolutamide for non-metastatic castration-resistant prostate cancer (nmCRPC). Dr. Morgans explains that darolutamide, approved after the ARAMIS phase 3 trial, significantly improves metastasis-free survival by 22 months and reduces mortality by 31% compared to placeb...

Navigating Non-Metastatic Castration-Resistant Prostate Cancer Treatment in the PSMA PET Era - Neal Shore

Details
Zach Klaassen discusses the evolving landscape of non-metastatic castration-resistant prostate cancer (nmCRPC) with Neal Shore. They delve into the significant impact of PSMA PET scans on diagnosing and treating nmCRPC. Dr. Shore reflects on three pivotal trials—SPARTAN, PROSPER, and ARAMIS—that have redefined treatment approaches by demonstrating the efficacy of apalutamide, enzalutamide, and dar...

Non-Metastatic Castration-Resistant Prostate Cancer in the Era of PSMA PET Imaging - Aaron Berger

Details
Zach Klaassen and Aaron Berger explore the evolving landscape of non-metastatic castration-resistant prostate cancer (nmCRPC). Dr. Berger highlights the decreasing frequency of non-metastatic CRPC in clinical settings, attributing this shift to advanced imaging techniques, especially PSMA PET scans, which more accurately detect metastatic stages. He notes that in 2022 and 2023, only about 8% of ne...

The Impact of Advanced Imaging on Detection and Treatment in Nonmetastatic CRPC - Vahan Kassabian

Details
Zach Klaassen engages in a discussion with Vahan Kassabian about the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC) management. They delve into how novel imaging techniques, particularly PSMA PET scans, have had an impact in diagnosing nmCRPC by identifying metastases not detected by traditional imaging. Dr. Kassabian highlights the importance of PSA kinetics in...

Navigating the Nuances: Exploring Imaging Options and Impact to Treatment Strategies in nmCRPC - Ryan Malone

Details
Zach Klaassen and Ryan Malone discuss the management of Nonmetastatic castration-resistant prostate cancer (nmCRPC), focusing on the evolving role of PSMA PET imaging. They highlight the importance of defining PSA progression and the challenges posed by new imaging techniques in identifying low-volume disease. The discussion covers landmark trials and their implications for treatment options, emph...

Delaying Time to Metastasis in Patients With High-Risk, M0 CRPC With Radiolabeled J591 Plus Ketoconazole and Hydrocortisone - Scott Tagawa

Details
Scott Tagawa joins Alicia Morgans to discuss a randomized phase II study on a salvage anti-PSMA radioimmunotherapy targeting non-metastatic CRPC population. The study enrolled patients with high-risk non-metastatic CRPC, defined as a PSA doubling time of less than eight months or an absolute PSA of at least 20, low testosterone, and non-metastatic as defined by no evidence of metastasis on CT or M...

mCRPC: Combining and Sequencing LUGPA 2022 Presentation - Evan Yu

Details
At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Evan Yu presented on metastatic castration-resistant prostate cancer (mCRPC) combining and sequencing. Biography: Evan Yu, MD , Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Clinical Research...

Progression Patterns by Types of Metastatic Spread, PSA, and Clinical Symptoms - Post-Hoc Analyses of ARAMIS - Alicia Morgans

Details
Neal Shore interviews Alicia Morgans about her poster presentation on the ARAMIS trial. The ARAMIS trial evaluated darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) patients with rising PSA levels and no radiographic evidence of disease. The study found that the combination of ADT and darolutamide extended metastasis-free survival by about two years and increased overall...

Genomic and Clinical Markers in nmCRPC APCCC 2022 Presentation - Joaquin Mateo

Details
Joaquin Mateo delivers a comprehensive talk on the challenges and opportunities of using genomic and clinical markers in non-metastatic castration-resistant prostate cancer (CRPC). Dr. Mateo emphasizes that while prognostic biomarkers can inform the likely course of the disease, there's currently no data to suggest that molecular profiling can improve patient outcomes in non-metastatic CRPC. He ar...

Optimizing Treatment for High-Risk M0CRPC - Laura-Maria Krabbe

Details
In a conversation between Alicia Morgans and Professor Laura-Maria Krabbe, they discuss the treatment of non-metastatic, castration-resistant prostate cancer (M0CRPC). They highlight the importance of identifying high-risk patients based on PSA doubling time and the need for treatment intensification in this population. They also mention the role of PSMA PET scans in determining the extent of dise...